Cited by 711SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingAnimal Virus Infections Studies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Open access

Nie, Jianhui, Li, Qianqian, Wu, Jiajing, Zhao, Chenyan, Hao, Huan, Liu, Huan, Zhang, Li, Nie, Lingling, Qin, Haiyang, Wang, Meng, Lu, Qiong, Li, Xiaoyu, Sun, Qiyu, Liu, Junkai, Fan, Changfa, Huang, Weijin, Xu, Miao, Wang, Youchun·2020·Emerging Microbes & Infections

DOI 10.1080/22221751.2020.1743767PMC PMC7144318

Open this paper in CoChat — free account

Abstract

Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/22221751.2020.1743767

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Verification of the incorporaiton of SARS-CoV-2 spike protein in the pseudovirus. The surface proteins of the particle were investigated using western blotting (A), from left to right lane showing VSV pseudovirus, medium control and SARS-CoV-2 pseudovirus. The VSV pseudotyped virus and cell culture medium were prepared with the same procedure and used as negative control and pseudovirus negative control. The SARS-CoV-2 pseudovirus, together with G*ΔG-VSV, were tested against VSV G specific antibody (B).CC BY · PubMed Central

Figure 2. Selection of the cell line. Six types of cells were tested for VSV (A), and SARS-CoV-2 (B) pseudoviruses. The y-axis showed the absolute RLU value detected 24 h after pseudovirus infection. Cell backgrounds without pseudovirus infection were shown in figure C.CC BY · PubMed Central

Figure 3. Optimization of cell numbers for neutralization. (A) Effect of cells numbers on the titration of pseudovirus. The y-axis showed the RLU fold over the cell background. (B) Effect of cells numbers on the neutralization. Cell numbers and corresponding R2 values were list in the tables. A serum sample from a healthy individual was tested as negative control shown in black lines and symbols.CC BY · PubMed Central

Figure 4. Optimization of virus dose for neutralization. The viral inocula with a dose range starting from 41 to 1300 TCID50/well were tested for SARS-CoV-2 PBNA. A serum sample from a healthy individual was tested as negative control shown in black lines and symbols.CC BY · PubMed Central

Figure 5. Validation of the SARS-CoV-2 PBNA. (A) Specificity of the PBNA. A negative sample panel of seventy-four human and forty-six mouse serum samples were used to determine the specificity of this assay. (B) Inhibition curves for two SARS-CoV-2 convalescent patient serum samples and two negative serum samples derived from human and mouse. Typical four-parameter inhibition curves were observed for these two samples between log-transformed dilution and inhibition rate. The initial dilutions for positive and negative samples were 1:30 and 1:10 respectively, followed by 3-fold serial dilution. (C) Linear range for the PBNA. When the inhibition rate is in the range of 20%–80%, there is a linear relationship between the readout of the test sample and its dilution. (D) Reproducibility of the PBNA. A mixture of two SARS-CoV-2 coalescent patient serum samples was tested a total of 18 times on individual plates in three independent runs.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Self-citation
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citation
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citation
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China
Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X. L., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,386
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
The Novel Coronavirus Originating in Wuhan, China
Phelan, A., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,210
Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines
Whitt, M. A. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.08.006 · Cited by 431

Show all 27 references

Sorted by citations

Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J., Du, P. F., Wei, D., Yang, Z., Sun, X., Gong, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00426-x · Cited by 1,630
Self-citation
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504
Self-citation
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420
Self-citation
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382

See all 711

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0394-5 · Cited by 427
Detection of Neutralizing Antibodies in Serum Samples Using a SARS‐CoV‐2 Pseudotyped Virus Assay
Ferrero, S., Batto, M. V., Gatto, M. I., Dimase, F., & Helguera, G. F. (2024) · Current Protocols · doi:10.1002/cpz1.70025
Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay
Tolah, A. M., Sohrab, S. S., Tolah, K. M., Hassan, A. M., El-Kafrawy, S. A., & Azhar, E. I. (2021) · Diagnostics · doi:10.3390/diagnostics11060994 · Cited by 34
Design and Development of a Pseudotyped-lentivirus for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Hassannia, H., Enderami, S. E., Mansour, R. N., Eftekhary, M., Abazari, M., & Salarinia, R. (2023) · DOAJ (DOAJ: Directory of Open Access Journals)
Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2
Balinsky, C. A., Jani, V., Sun, P., Williams, M., Defang, G. N., & Porter, K. R. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2111-0_21 · Cited by 5
Development of a SARS‐CoV‐2 neutralization assay based on a pseudotyped virus using a HIV system
Liang, Z., Tong, J., Wu, X., Liu, S., Wu, J., Yu, Y., Zhang, L., Zhao, C., Lu, Q., Nie, J., et al. (2024) · MedComm · doi:10.1002/mco2.517 · Cited by 6
Validation of SARS-CoV-2 neutralization assay using VSV-based pseudovirus system
Artarini, A., Tan, M. I., Giri-Rachman, E. A., Natalia, D., Chen, D. V., Ono, C., & Matsuura, Y. (2026) · Analytical Biochemistry · doi:10.1016/j.ab.2026.116239
A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation
Cai, Z., Kalkeri, R., Zhu, M., Cloney-Clark, S., Haner, B., Wang, M., Osman, B., Dent, D., Feng, S.-L. Y., Longacre, Z., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12030501 · Cited by 14
Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes
Zettl, F., Meister, T. L., Vollmer, T., Fischer, B., Steinmann, J., Krawczyk, A., V’kovski, P., Tödt, D., Steinmann, E., Pfaender, S., et al. (2020) · Vaccines · doi:10.3390/vaccines8030386 · Cited by 85
A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter
Tsai, W.-Y., Ching, L. L., Hsieh, S., Melish, M. E., Nerurkar, V. R., & Wang, W. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1925163 · Cited by 22

Authors: Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Fan, C., Huang, W., Xu, M., & Wang, Y.
Affiliations: National Institutes for Food and Drug Control (CN)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author: Huang, Weijin
Xu, Miao
Wang, Youchun
ORCID: Nie, Jianhui
Li, Qianqian
Wu, Jiajing
Zhao, Chenyan
Liu, Huan
Zhang, Li
Nie, Lingling
Wang, Meng
Lu, Qiong
Li, Xiaoyu
Sun, Qiyu
Fan, Changfa
Huang, Weijin
Xu, Miao
Wang, Youchun
Venue: Emerging Microbes & Infections
Publisher: Informa UK Limited
Published: 2020-01
Volume: 9
Issue: 1
Pages: 680-686
ISSN: 2222-1751 (ISSN-L)
DOI: 10.1080/22221751.2020.1743767
PMC: PMC7144318
OpenAlex: W3012650581
Cited by: 711
References: 27
Citations by year: 2026: 21 · 2025: 37 · 2024: 73 · 2023: 95 · 2022: 157 · 2021: 186 · 2020: 141
FWCI: 19.06
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Emerging Microbes & Infections (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: SARS-CoV-2, pseudovirus neutralization assay, neutralizing antibodies, biosafety level 2, convalescent sera, assay validation, detection limit, cut-off values, COVID-19 treatment
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Serotherapy, Animals, Antibodies, Viral, Cell Line, Humans, Immune Sera, Immunization, Passive, Membrane Glycoproteins, Neutralization Tests, Plasmids, Pneumonia, Viral, Sensitivity and Specificity, Vesicular stomatitis Indiana virus, Viral Envelope Proteins, Reproducibility of Results, Coronavirus Infections, Mice, Virus Internalization, Antibodies, Neutralizing, Limit of Detection, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks